阿达木单抗生物类似药治疗非感染性葡萄膜炎的疗效与原研药相似
该多中心回顾性队列研究纳入148例非感染性葡萄膜炎患者共260只眼,比较阿达木单抗生物类似药与原研药作为初始生物制剂治疗的疗效。12个月时原研药组估计复发率为24.2%,生物类似药组为28.3%(相对风险=1.17,95%CI 0.58至1.77)。研究提示生物类似药在预防疾病复发方面不劣于原研药。
要点
- 260只眼中原研药组193只(74.23%),生物类似药组67只(25.77%)。
- 12个月估计复发率原研药组24.2% vs 生物类似药组28.3%(相对风险=1.17,95%CI 0.58至1.77)。
- 12个月内平均复发时间原研药组4.91个月 vs 生物类似药组5.04个月(平均差0.13个月,95%CI -1.33至1.54个月)。
核心结论
- 研究提示,使用12个月时,阿达木单抗生物类似药在预防难治性非感染性葡萄膜炎患者疾病复发方面不劣于原研药。
- 这些结果支持使用阿达木单抗生物类似药治疗非感染性葡萄膜炎。
研究设计与样本
- 多中心回顾性队列研究,纳入148例非感染性葡萄膜炎患者共260只眼。
- 原研阿达木单抗组193只眼(74.23%),生物类似药组67只眼(25.77%)。
主要发现
- 葡萄膜炎复发共97只眼(37.31%),其中原研药组76只眼、生物类似药组21只眼。
- 12个月时估计复发率原研药组24.2% vs 生物类似药组28.3%(相对风险=1.17,95%CI 0.58至1.77)。
- 12个月随访内平均复发时间原研药组4.91个月 vs 生物类似药组5.04个月(平均差0.13个月,95%CI -1.33至1.54个月)。
- 未复发患者的中位随访时间为24.0个月(IQR 18.0,24.0)。
关键数值与推荐
- 复发定义为临床诊断的眼内炎症,需增加或改变局部或全身免疫抑制治疗。
- 按眼记录阿达木单抗治疗开始后的葡萄膜炎复发事件。
临床怎么用
- 原文结论支持使用阿达木单抗生物类似药治疗非感染性葡萄膜炎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To compare the efficacy in achieving and maintaining control of inflammation between adalimumab biosimilars and originator adalimumab as initial biologic treatment among patients with non-infectious uveitis (NIU). METHODS: This is a multicentre retrospective cohort study. Events of uveitis relapse were noted per eye following initiation of adalimumab treatment. Relapses were defined as the clinical diagnosis of intraocular inflammation, requiring an increase or change in local or systemic immunosuppression. Relapse rates and time to first relapse by 12 months were compared between eyes treated with originator adalimumab or a biosimilar. RESULTS: 260 eyes of 148 patients diagnosed with NIU were treated with either originator adalimumab (n=193, 74.23%) or a biosimilar (n=67, 25.77%). Median follow-up from baseline for patients who did not relapse was 24.0 months (IQR 18.0, 24.0). Uveitis relapses occurred in 97 eyes (37.31%, 76 in the originator adalimumab group and 21 in the biosimilar group). By 12 months, the estimated relapse rate was 24.2% in the originator adalimumab group versus 28.3% in the biosimilar group (relative risk=1.17, 95% CI 0.58 to 1.77). The average time to relapse by 12 months follow-up for the originator adalimumab group was 4.91 months compared with 5.04 months in the biosimilar group (mean difference 0.13 months, 95% CI -1.33 to 1.54 months). CONCLUSION: Our study suggests that by 12 months of use, biosimilar adalimumab agents were not inferior to originator adalimumab in preventing disease relapse among patients with refractory NIU. These results support the use of biosimilar adalimumab for treating NIU.
引用
- Tomkins-Netzer O, Niederer RL, Amer R, et al. Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitis. Br J Ophthalmol. 2025. PMID: 40645669. doi:10.1136/bjo-2025-327767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。